Safety and Tolerability of Odanacatib Therapy in Postmenopausal Women with Osteoporosis: Results from the Phase III Long-Term Odanacatib Fracture Trial (LOFT)
Socrates E. Papapoulos(Leiden University Medical Center), Deborah M. Gurner(Merck & Co., Inc., Rahway, NJ, USA (United States)), Assunta Lombardi, Henry G. Bone(University of Arizona), José Zanchetta(Universidad del Salvador), C.L. de Tilleghem, Xia Ling(Hunan University), Michael R. McClung(Bone Health and Osteoporosis Foundation), J Walliser, C. Roux, Pothuru Anil Kumar, Arthur C. Santora(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kurt Lippuner(University of Bern), A. Fybak-Feiglin, Ian R. Reid(University of Auckland), T. Nakamura, Nadia Verbruggen(Merck & Co., Inc., Rahway, NJ, USA (United States)), Bente Langdahl(Aarhus University Hospital), C.A. da Silva, Dosinda Cohn(Merck & Co., Inc., Rahway, NJ, USA (United States)), Cristiano A. F. Zerbini(Centro Paulista de Investigação Clinica), J.-Y. Reginster(University of Liège), DP Kiel, T. de Villiers, Albert Leung(Merck & Co., Inc., Rahway, NJ, USA (United States)), S. Adámi, B. B. Scott, Awc Kung(University of Hong Kong), K. Saag, Sung Kil Lim, C. Mautalén, N B Watts, Jose Adolfo Rodriguez-Portales(Pontificia Universidad Católica de Chile)
Data Archiving and Networked Services (DANS)
February 28, 2014
Cited by 3
Related Papers
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
|New England Journal of Medicine|2020|15.7k
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
|New England Journal of Medicine|2014|1.2k